Literature DB >> 18381405

Identification of p18 INK4c as a tumor suppressor gene in glioblastoma multiforme.

David A Solomon1, Jung-Sik Kim, Sultan Jenkins, Habtom Ressom, Michael Huang, Nicholas Coppa, Lauren Mabanta, Darell Bigner, Hai Yan, Walter Jean, Todd Waldman.   

Abstract

Genomic alterations leading to aberrant activation of cyclin/cyclin-dependent kinase (cdk) complexes drive the pathogenesis of many common human tumor types. In the case of glioblastoma multiforme (GBM), these alterations are most commonly due to homozygous deletion of p16(INK4a) and less commonly due to genomic amplifications of individual genes encoding cyclins or cdks. Here, we describe deletion of the p18(INK4c) cdk inhibitor as a novel genetic alteration driving the pathogenesis of GBM. Deletions of p18(INK4c) often occurred in tumors also harboring homozygous deletions of p16(INK4a). Expression of p18(INK4c) was completely absent in 43% of GBM primary tumors studied by immunohistochemistry. Lentiviral reconstitution of p18(INK4c) expression at physiologic levels in p18(INK4c)-deficient but not p18(INK4c)-proficient GBM cells led to senescence-like G(1) cell cycle arrest. These studies identify p18(INK4c) as a GBM tumor suppressor gene, revealing an additional mechanism leading to aberrant activation of cyclin/cdk complexes in this terrible malignancy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18381405      PMCID: PMC4394609          DOI: 10.1158/0008-5472.CAN-07-6388

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  20 in total

1.  Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin.

Authors:  T A Libermann; H R Nusbaum; N Razon; R Kris; I Lax; H Soreq; N Whittle; M D Waterfield; A Ullrich; J Schlessinger
Journal:  Nature       Date:  1985 Jan 10-18       Impact factor: 49.962

2.  The consensus coding sequences of human breast and colorectal cancers.

Authors:  Tobias Sjöblom; Siân Jones; Laura D Wood; D Williams Parsons; Jimmy Lin; Thomas D Barber; Diana Mandelker; Rebecca J Leary; Janine Ptak; Natalie Silliman; Steve Szabo; Phillip Buckhaults; Christopher Farrell; Paul Meeh; Sanford D Markowitz; Joseph Willis; Dawn Dawson; James K V Willson; Adi F Gazdar; James Hartigan; Leo Wu; Changsheng Liu; Giovanni Parmigiani; Ben Ho Park; Kurtis E Bachman; Nickolas Papadopoulos; Bert Vogelstein; Kenneth W Kinzler; Victor E Velculescu
Journal:  Science       Date:  2006-09-07       Impact factor: 47.728

3.  Amplification and expression of cyclin D genes (CCND1, CCND2 and CCND3) in human malignant gliomas.

Authors:  R Büschges; R G Weber; B Actor; P Lichter; V P Collins; G Reifenberger
Journal:  Brain Pathol       Date:  1999-07       Impact factor: 6.508

4.  PTEN gene mutations are seen in high-grade but not in low-grade gliomas.

Authors:  B K Rasheed; T T Stenzel; R E McLendon; R Parsons; A H Friedman; H S Friedman; D D Bigner; S H Bigner
Journal:  Cancer Res       Date:  1997-10-01       Impact factor: 12.701

5.  Homozygous deletions of the CDKN2C/p18INK4C gene on the short arm of chromosome 1 in anaplastic oligodendrogliomas.

Authors:  U Pohl; J G Cairncross; D N Louis
Journal:  Brain Pathol       Date:  1999-10       Impact factor: 6.508

6.  A Fas-associated protein factor, FAF1, potentiates Fas-mediated apoptosis.

Authors:  K Chu; X Niu; L T Williams
Journal:  Proc Natl Acad Sci U S A       Date:  1995-12-05       Impact factor: 11.205

7.  Haploinsufficiency of p18(INK4c) sensitizes mice to carcinogen-induced tumorigenesis.

Authors:  Feng Bai; Xin-Hai Pei; Virginia L Godfrey; Yue Xiong
Journal:  Mol Cell Biol       Date:  2003-02       Impact factor: 4.272

8.  CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas.

Authors:  E E Schmidt; K Ichimura; G Reifenberger; V P Collins
Journal:  Cancer Res       Date:  1994-12-15       Impact factor: 12.701

9.  Growth suppression by p18, a p16INK4/MTS1- and p14INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function.

Authors:  K L Guan; C W Jenkins; Y Li; M A Nichols; X Wu; C L O'Keefe; A G Matera; Y Xiong
Journal:  Genes Dev       Date:  1994-12-15       Impact factor: 11.361

10.  Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection.

Authors:  C Li; W H Wong
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-02       Impact factor: 11.205

View more
  28 in total

1.  Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM.

Authors:  W Ruprecht Wiedemeyer; Ian F Dunn; Steven N Quayle; Jianhua Zhang; Milan G Chheda; Gavin P Dunn; Li Zhuang; Joseph Rosenbluh; Shujuan Chen; Yonghong Xiao; Geoffrey I Shapiro; William C Hahn; Lynda Chin
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-07       Impact factor: 11.205

Review 2.  Studying a complex tumor: potential and pitfalls.

Authors:  Siyuan Zheng; Milan G Chheda; Roel G W Verhaak
Journal:  Cancer J       Date:  2012 Jan-Feb       Impact factor: 3.360

3.  PTEN status switches cell fate between premature senescence and apoptosis in glioma exposed to ionizing radiation.

Authors:  J-J Lee; B C Kim; M-J Park; Y-S Lee; Y-N Kim; B L Lee; J-S Lee
Journal:  Cell Death Differ       Date:  2010-11-12       Impact factor: 15.828

Review 4.  Gene therapy and virotherapy: novel therapeutic approaches for brain tumors.

Authors:  Kurt M Kroeger; A K M Ghulam Muhammad; Gregory J Baker; Hikmat Assi; Mia K Wibowo; Weidong Xiong; Kader Yagiz; Marianela Candolfi; Pedro R Lowenstein; Maria G Castro
Journal:  Discov Med       Date:  2010-10       Impact factor: 2.970

5.  Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts.

Authors:  Karine Michaud; David A Solomon; Eric Oermann; Jung-Sik Kim; Wei-Zhu Zhong; Michael D Prados; Tomoko Ozawa; C David James; Todd Waldman
Journal:  Cancer Res       Date:  2010-03-30       Impact factor: 12.701

Review 6.  Targeted therapy for malignant glioma patients: lessons learned and the road ahead.

Authors:  Tiffany T Huang; Shawn M Sarkaria; Timothy F Cloughesy; Paul S Mischel
Journal:  Neurotherapeutics       Date:  2009-07       Impact factor: 7.620

7.  Sample type bias in the analysis of cancer genomes.

Authors:  David A Solomon; Jung-Sik Kim; Habtom W Ressom; Zita Sibenaller; Timothy Ryken; Walter Jean; Darell Bigner; Hai Yan; Todd Waldman
Journal:  Cancer Res       Date:  2009-06-30       Impact factor: 12.701

8.  RADIO-IBAG: RADIOMICS-BASED INTEGRATIVE BAYESIAN ANALYSIS OF MULTIPLATFORM GENOMIC DATA.

Authors:  Youyi Zhang; Jeffrey S Morris; Shivali Narang Aerry; Arvind U K Rao; Veerabhadran Baladandayuthapani
Journal:  Ann Appl Stat       Date:  2019-10-17       Impact factor: 2.083

9.  Mutational inactivation of PTPRD in glioblastoma multiforme and malignant melanoma.

Authors:  David A Solomon; Jung-Sik Kim; Julia C Cronin; Zita Sibenaller; Timothy Ryken; Steven A Rosenberg; Habtom Ressom; Walter Jean; Darell Bigner; Hai Yan; Yardena Samuels; Todd Waldman
Journal:  Cancer Res       Date:  2008-12-15       Impact factor: 12.701

10.  p18Ink4c and p53 Act as tumor suppressors in cyclin D1-driven primitive neuroectodermal tumor.

Authors:  Raya Saab; Carlos Rodriguez-Galindo; Kelly Matmati; Jerold E Rehg; Shannon H Baumer; Joseph D Khoury; Catherine Billups; Geoffrey Neale; Kathleen J Helton; Stephen X Skapek
Journal:  Cancer Res       Date:  2009-01-15       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.